Sliwkowski MX - Search Results

1

Yarden Y, Sliwkowski MX. Yarden Y, et al. Among authors: sliwkowski mx. Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37. doi: 10.1038/35052073. Nat Rev Mol Cell Biol. 2001. PMID: 11252954 Review.

2

Ready to partner.

Sliwkowski MX. Sliwkowski MX. Nat Struct Biol. 2003 Mar;10(3):158-9. doi: 10.1038/nsb0303-158. Nat Struct Biol. 2003. PMID: 12605220 No abstract available.

3

Treatment of HER2-positive breast cancer: current status and future perspectives.

Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Arteaga CL, et al. Among authors: sliwkowski mx. Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32. doi: 10.1038/nrclinonc.2011.177. Nat Rev Clin Oncol. 2011. PMID: 22124364 Review.

4

Perspectives on anti-HER monoclonal antibodies.

Ranson M, Sliwkowski MX. Ranson M, et al. Among authors: sliwkowski mx. Oncology. 2002;63 Suppl 1:17-24. doi: 10.1159/000066203. Oncology. 2002. PMID: 12422051 Review.

5

High cell-surface density of HER2 deforms cell membranes.

Chung I, Reichelt M, Shao L, Akita RW, Koeppen H, Rangell L, Schaefer G, Mellman I, Sliwkowski MX. Chung I, et al. Among authors: sliwkowski mx. Nat Commun. 2016 Sep 7;7:12742. doi: 10.1038/ncomms12742. Nat Commun. 2016. PMID: 27599456 Free PMC article.

6

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX. Agus DB, et al. Among authors: sliwkowski mx. Cancer Cell. 2002 Aug;2(2):127-37. doi: 10.1016/s1535-6108(02)00097-1. Cancer Cell. 2002. PMID: 12204533

7

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.

Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S. Burgess AW, et al. Among authors: sliwkowski mx. Mol Cell. 2003 Sep;12(3):541-52. doi: 10.1016/s1097-2765(03)00350-2. Mol Cell. 2003. PMID: 14527402 Review.

8

HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment.

Zigler M, Shir A, Joubran S, Sagalov A, Klein S, Edinger N, Lau J, Yu SF, Mizraji G, Globerson Levin A, Sliwkowski MX, Levitzki A. Zigler M, et al. Among authors: sliwkowski mx. Cancer Immunol Res. 2016 Aug;4(8):688-97. doi: 10.1158/2326-6066.CIR-15-0203. Epub 2016 May 30. Cancer Immunol Res. 2016. PMID: 27241844

9

Oncogenic ERBB3 mutations in human cancers.

Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, Chaudhuri S, Pujara K, Guillory J, Edgar KA, Janakiraman V, Scholz RP, Bowman KK, Lorenzo M, Li H, Wu J, Yuan W, Peters BA, Kan Z, Stinson J, Mak M, Modrusan Z, Eigenbrot C, Firestein R, Stern HM, Rajalingam K, Schaefer G, Merchant MA, Sliwkowski MX, de Sauvage FJ, Seshagiri S. Jaiswal BS, et al. Among authors: sliwkowski mx. Cancer Cell. 2013 May 13;23(5):603-17. doi: 10.1016/j.ccr.2013.04.012. Cancer Cell. 2013. PMID: 23680147

10

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.

Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX. Junttila TT, et al. Among authors: sliwkowski mx. Cancer Cell. 2009 May 5;15(5):429-40. doi: 10.1016/j.ccr.2009.03.020. Cancer Cell. 2009. PMID: 19411071

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results